Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a single center phase 1 trail to observe safety and efficacy of metronomic
capecitabine plus PD-L1 antibody camrelizumab as third-line regimen to treat HER2 negative
advanced gastric cancer patients.
This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic
capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.